AQEMIA Achieves Research Milestone Against Undruggable Target in Immuno-Oncology with Servier
2024年6月28日 - 2:30PM
ビジネスワイヤ(英語)
AQEMIA, a leading company in generative-AI-driven drug
discovery, announces the achievement of a research milestone in its
collaboration with Servier, an international independent
pharmaceutical company, to address an undruggable target in
immuno-oncology.
Based on AQEMIA ‘s quantum and statistical physics-based
calculations, and within the span of a few months, a series of
molecules experimentally active on an undruggable target in
immuno-oncology have been successfully identified. This milestone
triggers an undisclosed payment to AQEMIA.
"Our teams are very proud of this achievement that demonstrates
the power of AQEMIA's cutting-edge generative AI and deep physics
in creating novel, patentable molecules to meet therapeutic needs
that are still immense, particularly in the field of
immuno-oncology. Within the framework of our collaboration with
Servier, we have reached the stage where a series of molecules are
subsequently proven impactful in vitro and in vivo assays. " said
Maximilien Levesque, PhD, CEO and Co-founder of AQEMIA.
This critical milestone is a continuation of Servier and
AQEMIA’s successful partnership program, initiated in December
2021, to accelerate drug candidate discovery in immuno-oncology
using artificial intelligence and deep physics.
AQEMIA has worked on more than a dozen in-house therapeutic
programs in oncology and immuno-oncology, as well as in new
therapeutic areas such as immunology, inflammation and diseases of
the central nervous system. To date, AQEMIA’s three most advanced
programs are being tested against cancers in animals.
About AQEMIA AQEMIA is a next-gen techbio generating one
of the world's fastest-growing drug discovery pipeline. Our mission
is to design fast many innovative drug candidates for critical
diseases. Our differentiation lies in our unique quantum and
statistical mechanics algorithms to power a generative artificial
intelligence designing novel drug candidates, without the need to
train on experimental data. We already delivered several drug
discovery successes in internal pipeline as well as in
collaboration with Pharma companies - most advanced programs being
currently in vivo optimization.
For more information, visit AQEMIA.com and our LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240627468833/en/
For media inquiries, please contact: Orianne
Bornand Head of Communications +33 6 10 04 32 80
orianne.bornand@aqemia.com
Ingrid Delval Chief of Staff to the CEO
ingrid.delval@aqemia.com